Romvimza
What Romvimza is used for
Romvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Romvimza
- Active substance
- vimseltinib
- Disease area
- Giant Cell Tumor of Tendon Sheath
- Medicine group
- Antineoplastic agents
- ATC code
- L01EX
- Marketing authorisation holder
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Romvimza used for?
Romvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
What is the active substance in Romvimza?
Romvimza contains vimseltinib.
Who makes Romvimza?
The EU marketing authorisation holder is Deciphera Pharmaceuticals (Netherlands) B.V..
Is Romvimza an orphan medicine?
Yes. Romvimza is designated an orphan medicine in the EU, for a rare disease (Giant Cell Tumor of Tendon Sheath).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU